An observational study in Mitral Regurgitation, sponsored by Universitätsklinikum Hamburg-Eppendorf. Recruiting at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-18.
Sponsored by Universitätsklinikum Hamburg-Eppendorf · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Mitral Valve Insufficiency with a site in France — 17 open to participants now, 21 under way, none of them phase 3. Mitral Valve Insufficiency · France.
Among the 42 studies in Mitral Valve Insufficiency with a site in France, this one has the largest planned enrollment of the 16 observational ones that give a count, is one of 2 that started in 2022, is one of 16 observational ones, reaches primary completion later than 5 of the 20 other live ones, and was the 35th registered.
471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.
Browse Mitral Valve Insufficiency studies →17 of the 42 studies in Mitral Valve Insufficiency with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
4C Medical Technologies, Inc. · Sites in France, United States, Canada and 4 more countries
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Medtronic Cardiovascular · Sites in France, Denmark, Germany and 5 more countries
Ages 18+
HighLife SAS · Sites in France, Australia, Belgium and 3 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2022.
This study's planned enrollment of 2,000 is above the median of 159 across 170 observational studies indexed under Mitral Valve Insufficiency.
Median enrollment 57 across the 26 interventional studies, 470 across the 16 observational. Of the 12 that completed or were terminated, 5 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 42 have an industry lead sponsor. The 10 most frequent:
Universitätsklinikum Hamburg-Eppendorf is the lead sponsor of 416 studies on the registry; 86 are open to participants now.
Universitätsklinikum Hamburg-Eppendorf has 2 studies filed under Mitral Valve Insufficiency — fewer than ten, so there is no comparison to draw.
5 of the studies in Mitral Valve Insufficiency with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03271762Nantes University HospitalMulticentre Study of MITRACLIP® Transcatheter Mitral Valve Repair in Patients With Severe Primary Mitral Regurgitation Eligible for High-risk Surgery | 2026-12 |
| NCT02925819French Cardiology SocietyManagement and Clinical Outcomes of Patients With Severe Mitral Valve Disease Not Suitable for Surgery | 2026-12 |
| NCT04029363HighLife SASExpanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk | 2026-12-15 |
| NCT03142152Cardiac Dimensions, Inc.The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | 2026-12-31 |
| NCT04898335LMU KlinikumTendyne European Experience Registry | 2026-12-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 42 studies in Mitral Valve Insufficiency with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This multinational, non-interventional, investigator-initiated, retrospective study aims to investigate outcomes of patients, who underwent mitral valve transcatheter edge-to-edge repair (M-TEER) for primary mitral regurgitation (PMR).
Consecutive patients undergoing transcatheter edge-to-edge repair for primary mitral regurgitation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with primary mitral regurgitation undergoing mitral valve transcatheter edge-to-edge repair.
All-cause mortality
Incidence of death from any cause.
Time frame: 12 months
Cardiovascular mortality
Incidence of cardiovascular death, defined as death attributable to myocardial ischemia and infarction, heart failure, cardiac arrest because of other or unknown cause, or cerebrovascular accident.
Time frame: 12 months
Rehospitalization for congestive heart failure
Incidence of new-onset or worsening signs and symptoms of heart failure that required urgent therapy and resulted in hospitalization, e.g. as assessed by patient interviews or medical records.
Time frame: 12 months
Re-do mitral valve procedure
Incidence of unplanned surgical (mitral valve repair or replacement) or transcatheter re-intervention (re-do transcatheter edge-to-edge repair), e.g. as assessed by patient interviews or medical records.
Time frame: 12 months
Residual mitral regurgitation
Mitral regurgitation severity (0, 1+, 2+, 3+, 4+) as assessed by transthoracic echocardiography at discharge.
Time frame: up to 30 days
Residual mitral regurgitation
Mitral regurgitation severity (0, 1+, 2+, 3+, 4+) as assessed by transthoracic echocardiography at 1-year follow-up.
Time frame: 12 months
MVARC (Mitral Valve Academic Research Consortium) Technical success
All of the following must be present: 1. Absence of procedural mortality 2. Successful access, delivery, and retrieval 3. Successful deployment and correct positioning of the first device 4. Freedom from emergency surgery or reintervention related to the device or access procedure
Time frame: 1 day (at exit from the catheterization laboratory)
Functional success
If one of the following is present: 1. Residual mitral regurgitation ≤2+ 2. Effective regurgitant orifice area ≤15 mm2 3. Transmitral gradient \<5 mmHg
Time frame: 1 day (at exit from the catheterization laboratory)
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2022 (actual). Primary completion is estimated for Jan 2025, 34 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitätsklinikum Hamburg-Eppendorf →